Chiral amino acid–based anthraquinones: synthesis, structural characterization, and structure–activity relationships in cancer cell lines
Metadatos
Afficher la notice complèteAuteur
Pérez, Juana M; Rodríguez Criado, Jorge; Quiñonero Muñoz, Francisco José; Gutiérrez Segura, Natalia; López-Vargas, Mireya E.; Forte-Castro, Arantxa; Ruiz Muelle, Ana Belén; Salcedo-Abraira, Pablo; Rodríguez Diéguez, Antonio; Melguizo Alonso, Consolación; Prados Salazar, José Carlos; Fernández, IgnacioEditorial
Elsevier
Materia
Anthraquinone Amino acids Nuclear magnetic resonance Cancer treatment
Date
2026-04Referencia bibliográfica
Pérez, J. M., Rodriguez-Criado, J., Quiñonero, F., Gutiérrez-Segura, N., López-Vargas, M. E., Forte-Castro, A., Ruiz-Muelle, A. B., Salcedo-Abraira, P., Rodríguez-Diéguez, A., Melguizo, C., Prados, J., & Fernández, I. (2026). Chiral amino acid–based anthraquinones: synthesis, structural characterization, and structure–activity relationships in cancer cell lines. Results in Chemistry, 22, 103121. https://doi.org/10.1016/j.rechem.2026.103121
Patrocinador
This research has been funded by the State Research Agency of the Spanish of Science, Innovation and Universities (PID2021–126445OBI00, PID2023-150047OA-I00 and CPP2022–009967), by Gobierno de Espana ˜ MCIN/AEI/10.13039/501100011033 and Union ´ Europea “Next Generation EU”/PRTR, by University of Almería “Proyecto de Investigacion ´ Lanzadera 2024” (P_LANZ_2024/ 009) and by Junta de Andalucía, Consejería de Universidad, Investigacion ´ e Innovacion ´ (DGP_PIDI_2024_00886). M.E.L-V and J.M.P. acknowledge the State Research Agency of the Spanish of Science, Innovation and Universities for the FPU (grant no. FPU22/01199) and University of Almería for the Hipatia grant (grant no. HIPATIA2021_04), respectively. P⋅S-A. thanks Grant JDC2022-048964-I funded by MICIU/AEI/10.130 39/501100011033 and by “European Union NextGeneratiRésumé
A new family of chiral amino acid-based anthraquinones has been synthesized and fully characterized by multinuclear magnetic resonance (1H, 13C and 15N), elemental analysis, UV–Vis spectroscopy, circular dichroism, single-crystal X-ray diffraction and infrared spectroscopy. These molecules have been studied in different cancer cell lines (PANC-1, MCF-7, A549, SF268, HCT116) and a non-tumoral cell line (L-929) through different in vitro assays. The results showed that these molecules had dose-dependent antitumor effects, with compound 4e showing the lowest IC50 values across most tumor cell lines. Its crystal structure confirmed the enantiomeric purity and revealed π–π stacking interactions between anthraquinone and phenylalanine rings, features that may contribute to its enhanced biological performance. In addition, it was observed that the compounds had the ability to decrease cell migration and clonogenicity in the treated cell lines, demonstrating their ability to inhibit tumor malignancy processes. After studying possible molecular routes through which they induce their effect, it was shown that they are capable of inducing apoptosis and that they do not cause intracellular damage through the production of ROS. Therefore, these new synthesized compounds showed therapeutic potential in cancer, although further study of the molecular mechanisms involved in this antitumor activity is still needed.





